Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more

Conditions: Tuberculosis, Diabetes Mellitus
Interventions: BCG; Biological
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Thyroid Cancer, Papillary Microcarcinoma
Interventions: Focus groups; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: carboplatin, gemcitabine hydrochloride; Drug
Lead sponsor: AGO Study Group; Other
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Type 2 Diabetes
Interventions: Extra Virgin Olive Oil, Refined Olive Oil; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 25 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Gynecologic Cancer
Interventions: SIGNAL; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type2 Diabetes, Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Todd Doyle; Other
Eligibility: 40 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Type 2 Diabetes
Interventions: Metformin, Insulin Glargine, Dorzagliatin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Charlottesville, Virginia

Conditions: Chronic Kidney Diseases
Interventions: Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan; Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Polycystic Ovarian Syndrome, Infertility, Obesity, Overweight
Interventions: Vegan diet, Low calorie diet; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, pioglitazone, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Mesa, Arizona • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Pancreatic Cancer, Cancer Cachexia
Interventions: Baseline Lifestyle and Symptom Assessment, Extended Lifestyle Monitoring, Feasibility Survey; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitor and Undermyfork App, Continuous Glucose Monitor; Other
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene, Type 2 Diabetes, Sleep, Sleep Deprivation, Insufficient Sleep Syndrome
Interventions: Sleep Extension Intervention; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 2 Diabetes
Interventions: Colesevelam, Colesevelam matching placebo, Insulin glargine (Lantus); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes, Pregnancy
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Jackson, Mississippi + 7 more

Conditions: Type 2 Diabetes Mellitus, Type 2 Diabetes
Interventions: dutogliptin; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Norwalk, California • Orange, California • Santa Ana, California + 10 more

Conditions: Thyroid Cancer
Interventions: Radioactive Iodine 124; Radiation
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: paclitaxel poliglumex; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Growth Hormone Disorder, Pituitary Dwarfism
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 3 Years to 13 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 23 more

Conditions: Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst, Pancreatic Neuroendocrine Tumor, Pancreas; Insulinoma, Pancreatic Cyst, Pancreatic Teratoma, Pancreatic Polypeptide Tumor, Pancreatic Vipoma, Pancreatic Cystadenoma, Pancreas Injury, Pancreatic Gastrinoma, Pancreatic Glucagonoma
Interventions: Distal Pancreatectomy Sealing Using LTW; Device
Lead sponsor: Laser Tissue Welding, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Neuropathy
Interventions: Neuropathy/Ulcer Homeopathic topical cream; Other
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 1 Diabetes, Osteoporosis
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Immunobiology of Diabetes and Tuberculosis

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Healthy Eating for Reproductive Health: Greenville

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

A First-in-Human Study of FID-022 in Solid Tumor Patients

Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Effect of Sleep Extension on Ceramides in People With Overweight and Obesity

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot

Bone Health in Type 1 Diabetes